Special Issue "Preclinical Evidence on Anti-cancer Drug Discovery, Development and Delivery"

Submission Deadline: 30 November 2021 (closed)
Guest Editors
Dr. P. Ashok Kumar
Professor, School of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science and Technology, Vandalur, Chennai, India
Email: panduashokkumar@gmail.com

Dr. Norhaizan Mohd Esa
Associate Professor and Deputy Dean (Academics), University Putra Malaysia, Serdang, Malaysia.
E-Mail: nhaizan@upm.edu.my

Dr. Mohmamed Adil
Associate Professor, School of Allied and Health Sciences, Meenakshi Academy of Higher Education and Research, Chennai, India
E-Mail: adilmdaa@gmail.com

Summary

Cancer is a serious health issue worldwide affects men and women. Over the past half-decade, cancer doctors have focused solely on three treatment options: surgery, radiation therapy, and chemotherapy. During that time, tremendous advances in cancer biology have been developed, targeted anti-cancer drugs have arisen, and thousands of clinical trials have taught us how to better craft treatment formulations that maximize clinical outcomes. Current chemotherapeutic drugs are successful, but they come with a slew of negative side effects. Scientists are also searching for better anticancer agents with less side effects and more efficient delivery methods. This special issue will focus on archiving the manuscripts on new anticancer agents of Herbal extracts and its active ingredients, synthetic derivates from natural agents against cancer.


Keywords
Cancer, cancer prevention and therapy, Synthetic drugs, probiotics, natural products, synthetic peptides, nanoparticles